Do you want to read an article? Please log in or register.
A greater proportion of participants with type 2 diabetes achieve treatment targets with IDegLira (insulin degludec/liraglutide) versus insulin glargine U100 at 26 weeks: DUAL VIII a randomized trial designed to resemble clinical practice
Type 2 DiabetesGlycemic Control